Search Results

Your search for GARTH STROHBEHN, MD, MPhil; ALLEN LICHTER, MD, FASCO; AND MARK RATAIN, MD, FASCO matches 2 pages

Showing 1 - 2

By GARTH W. STROHBEHN, MD, MPhil; ALLEN S. LICHTER, MD, FASCO; AND MARK J. RATAIN, MD, FASCO / September 25, 2026

Old Habits Die Hard: Project Optimus and the Next Generation of KRAS G12C Inhibitors

The recent announcement1 that divarasib, a next-generation KRAS G12C inhibitor, improved both progression-free and overall survival compared with first-generation KRAS G12C inhibitors (ie, sotorasib, adagrasib) is an important scientific milestone in the treatment of KRAS G12C–mutated non–small...

issues in oncology

lung cancer

By GARTH STROHBEHN, MD, MPhil; ALLEN LICHTER, MD, FASCO; AND MARK RATAIN, MD, FASCO / February 25, 2024

Sotorasib, the Poster Child for Project Optimus: Truths and Fantasies

In January 2021, two of us wrote in these pages about our field’s pressing need to pivot away from identifying and deploying the maximum tolerated dose (MTD) when it comes to targeted oncology therapies.1 We argued that, instead, one should be looking for the “optimal dose”—the dose that best...

Sep

Today In Oncology

Search Results

Your search for GARTH STROHBEHN, MD, MPhil; ALLEN LICHTER, MD, FASCO; AND MARK RATAIN, MD, FASCO matches 2 pages

Old Habits Die Hard: Project Optimus and the Next Generation of KRAS G12C Inhibitors

Sotorasib, the Poster Child for Project Optimus: Truths and Fantasies

Cleveland Clinic to Host Second Annual AI Summit for Health-Care Professionals

Cleveland Clinic President Discusses AI Summit for Health-Care Professionals

AI’s Evolving Role in Clinical Care Enterprise-Wide

Long-Term Disease Control From SBRT Equal to Surgery in Localized Prostate Cancer

Cancer Statistics 2026: What Every Medical Oncologist Should Know